Introduction
Recombinant SARS-CoV-2 RBD domain with C-terminal His-tag, expressed into periplasm of E. coli.
Description
The spike (S) glycoprotein of coronaviruses mediates binding and entry of the virus into the host cell. The S protein is also a major immunogen and a target for development of antiviral drugs. The spike protein is a transmembrane protein composed of two subunits, S1 and S2. The S1 subunit contains a receptor-binding domain (RBD) responsible for binding to the receptor angiotensin-converting enzyme 2 (ACE2). Several mutants of the spike protein has been identified so far with various affinity to ACE2 and changed immunogenicity.
Application
ELISA, Western blot, LIA, Protein arrays
Purification method
Affinity chromatography.
Formulation
500 ug/mL, 10mM Tris pH 7.5, 50mM KCl
Specificity
RBD domain of the Spike protein (AA 319-541) from original Wuhan-Hu-1 isolate (NC_045512). The S477N mutation was found in lineage B.1.526, which has emerged late 2020 in the state of New York (USA).
Storage
-80°C. Aliquot upon arrival.
